EXPRESSION OF MATRIX METALLOPROTEINASE-2 IN THE MYOCARDIUM IN THE EXPERIMENTAL MODEL OF ANTHRACYCLINE CARDIOMYOPATHY

Abstract

The localization and expression of matrix metalloproteinase-2 (MMP-2) in the myocardium and their changes after administration of a sublethal dose (7 mg/kg) of doxorubicin hydrochloride were studied in male Wistar rats (n=28) with the use of an immunohistochemical analysis. MMP-2 in the myocardium of control and experimental animals was detected primarily in cardiomyocyte nuclei. With the development of anthracyclineinduced cardiomyopathy, there was an increase of the index of MMP-2 positive cardiomyocyte nuclei (2.6-fold by the 14th day of the experiment), while MMP-2 expression was also detected in the cardiomyocyte sarcoplasm. Positive correlation between the volume density of cardiomyocytes with lytic sarcoplasmic lesions and the index of MMP-2 positive cardiomyocyte nuclei was detected.

Keywords

cardiomyocytes / matrix metalloproteinase-2 / immunohistochemistry / anthracycline cardiomyopathy

References

[1] Клинникова М. Г., Лушникова Е. Л., Колдышева Е. В. и др. Кардиотоксический и дислипидемический эффекты доксорубицина и амида бетулоновой кислоты // Бюл. экспер. биол. 2016. Т. 162, № 8. С. 247-252.

[2] Непомнящих Л. М., Лушникова Е. Л., Семенов Д. Е. Регенераторно-пластическая недостаточность сердца: Морфологические основы и молекулярные механизмы. М.: Изд-во РАМН, 2003.

[3] Adamcova M., Potacova A., Popelova O. et al. Cardiac remodeling and MMPs on the model chronic daunorubicin-induced cardiomyopathy in rabbits // Physiol. Res. 2010. Vol. 59. P. 831- 836.

[4] Ali M. A., Fan X., Schulz R. Cardiac sarcomeric proteins: Novel intracellular targets of matrix metalloproteinase-2 in heart disease // Trends Cardiovasc. Med. 2011. Vol. 21 (4). P. 112-118.

[5] Aupperle H., Garbade J., Schubert A. et al. Effect of autologous stem cells on immunohistochemical patterns and gene expression of metalloproteinases and their tissue inhibitors in doxorubicin cardiomyopathy in a rabbit model // Vet. Pathol. 2007. Vol. 44 (4). P. 494-503.

[6] Baghirova S., Hughes B. G., Poirier M. et al. Nuclear matrix metalloproteinase-2 in the cardiomyocyte and the ischemic-reperfused heart // J. Mol. Cell. Cardiol. 2016. Vol. 94. P. 153-161.

[7] Bai P., Mabley J. G., Liaudet L. et al. Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity // Oncol. Rep. 2004. Vol. 11, № 2. P. 505-508.

[8] Cheung P.-Y., Sawicki G., Wozniak M. et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart // Circulation. 2000. Vol. 101, № 15. P. 1833-1839.

[9] Chow A. K., Cena J., Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature // Br. J. Pharmacol. 2007. Vol. 152, № 2. P. 189-205.

[10] Fan X., Hughes B. G., Ali M. A. et al. Matrix metalloproteinase-2 in oncostatin M-induced sarcomere degeneration in cardiomyocytes // Am. J. Physiol. Heart Circ. Physiol. 2016. Vol. 311, № 1. P. H183-189.

[11] Gao C. Q., Sawicki G., Suarez-Pinzon W. L. et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction // Cardiovasc. Res. 2003. Vol. 57, № 2. P. 426-433.

[12] Ivanova M., Dovinova I., Okruhlicova L. et al. Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats // Acta Pharmacol. Sin. 2012. Vol. 33, № 4. P. 459-469.

[13] Jacob-Ferreira A. L., Schulz R. Activation of intracellular matrix metalloproteinase-2 by reactive oxygen-nitrogen species: Consequences and therapeutic strategies in the heart // Arch. Biochem. Biophys. 2013. Vol. 540, № 1-2. P. 82-93.

[14] Kandasamy A. D., Chow A. K., Ali M. A. M., Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: Beyond the matrix // Cardiovasc. Res. 2010. Vol. 85. P. 413-423.

[15] Kwan J. A., Schulze C. J., Wang W. et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro // FASEB J. 2004. Vol. 18, № 6. P. 690-692.

[16] Malla N., Sjoli S., Winberg J. O. et al. Biological and pathobiological functions of gelatinase dimersand complexes// Connect. Tissue Res. 2008. Vol. 49. P. 180-184.

[17] Mitry M. A., Edwards J. G. Doxorubicin induced heart failure: Phenotype and molecular mechanisms // Int. J. Cardiol. Heart Vasc. 2016. Vol. 10. P. 17-24.

[18] Spinale F. G. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function // Physiol. Rev. 2007. Vol. 87, № 4. P. 1285-1342.

[19] Sung M. M., Schulz C. G., Wang W. et al. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury // J. Mol. Cell. Cardiol. 2007. Vol. 43, № 4. P. 429-436.

RIGHTS & PERMISSIONS

Eco-Vector